Tag: ReActiv8

Mainstay Medical announces headline results from ReActiv8-B clinical study

Mainstay Medical International, a medical device company focused on commercialising ReActiv8, an implantable restorative neurostimulation system designed to treat an underlying cause of disabling...

Mainstay Medical announces the completion of all implants in the ReActiv8-B...

Mainstay Medical International, a medical device company focused on bringing to market ReActiv8, an implantable neurostimulation system to treat chronic low back pain, announces...

Final ReActiv8 results: neurostimulation safe and effective treatment for chronic low...

Following implantation of a restorative neurostimulation system significant improvements were observed in pain, disability and quality of life compared to baseline in patients with...

Jason Hannon to replace Peter Crosby as Mainstay chief executive officer

Jason Hannon has been announced as successor to Peter Crosby as chief executive officer of Mainstay Medical, with effect from October 9, 2017. According...

First commercial implantation of Mainstay Medical’s ReActiv8 performed in Germany

The first commercial implantation of Mainstay Medical’s ReActiv8 has taken place in Germany. The implantation was performed by Francis Kilian, orthopaedic and neurosurgeon at the...

ReActiv8-A sustains performance at one year in clinical trial

Mainstay Medical International has announced the one-year results from the ReActiv8-A Clinical Trial, an international, multi-centre, prospective, single arm trial for ReActiv8 in people...

CE mark granted to Mainstay Medical for ReActiv8

Mainstay Medical International has received CE mark approval for ReActiv8, its proprietary implantable neurostimulation system designed to treat disabling chronic low back pain. According to...